Celyad enters into license agreement with ONO Pharmaceutical
Tuesday, July 12, 2016
Celyad enters into license agreement with ONO pharmaceutical Co., Ltd. to develop allogeneic NKR-2 T-cell immunotherapy.
Celyad grants an exclusive license to ONO for development and commercialization of Celyad's allogeneic NKR-2 t-cell in Japan, Korea and Taiwan.
Celyad also grants to ONO an exclusive option to license its autologous NKR-2 t cell product in above ONO territories.
Total deal value of up to JPY 31.325 bln (282 mln euros or $311.5 mln) plus double digit royalties on net sales in ono territories.
Celyad will receive an upfront payment of JPY 1.25 bln (11.25 million euros or $12.5 million).
Celyad is eligible of up to JPY 30.075 bln (270.75 mln euros or $299 mln) in development and commercial milestones.
Will also receive double digit royalties based on net sales of licensed product in ONO's territories.
Source : reuters.com
